Fractional Flow Reserve Computed Tomography

The Cardiovascular Imaging Core Laboratory was a partner in the NXT Trial that lead to Food and Drug Administration approval of HeartFlow fractional flow reserve computed tomography (FFR-CT) analysis – the first of its kind.

The Core Laboratory provided both FFR and quantitative coronary analysis (QCA) for the trial.

We played a key role in the first in U.S. clinical implementation of FFR-CT technology, which took place at University Hospitals in Cleveland, Ohio. Our experts’ guidance and insight resulted in significant improvement of the cardiac computed tomography (CCT) acquisition protocol and image quality. Our experts were also pivotal in the development of a new approach of a comprehensive coronary computed tomography angiography (CTA)-FFR-CT interpretation.